Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia.
about
Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignanciesComparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioningReduced-intensity and myeloablative conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis and systematic reviewMinimal residual disease testing to predict relapse following transplant for AML and high-grade myelodysplastic syndromes.Leukaemias into the 21st century: part 1: the acute leukaemias.Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.Survivorship after allogeneic transplantation-management recommendations for the primary care provider.Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease.Ara-C, Idarubicine and Gentuzumab Ozogamicin (AIM) as Salvage Treatment in Advanced Acute Myeloid Leukemia Patients.Allogeneic stem cell transplantation for adult acute lymphoblastic leukemia: when and how.Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT.Cytogenetic risk grouping by the monosomal karyotype classification is superior in predicting the outcome of acute myeloid leukemia undergoing allogeneic stem cell transplantation in complete remission.
P2860
Q34075082-E322F6A3-4A18-4FFC-A6DF-EDBC08279BE2Q34360641-DA49D957-33F3-4ACF-BF10-2E8BD92411B7Q34402494-E921B09E-C1CF-47BD-AEB6-37C0E5F5CD21Q34770016-56434F8E-13BE-4562-9E5F-18401349F7A3Q37872296-025F31A8-58A7-4619-92A3-73215EB6E21BQ38060223-D5B1DE5D-6C58-46CE-A8E5-C1DC4A340F3CQ38098957-E2F62AD6-F775-4E4C-AB47-41534967AF2BQ38350270-D2EB32F6-DC5E-4C4A-9351-908F45005015Q41896478-BC58DFEF-6BC7-4FC6-BA2B-F6F089FB8BD1Q42357653-2A82EEBD-C28E-4666-8E44-04C747B86BC8Q42852351-F20DC58C-F671-414B-B841-74685478F9BEQ44462895-59AF5ACB-EFEF-475A-9D6D-FE63C73FE7D8Q45233774-48216B33-B8E4-42A3-A4B9-E76FD99E1647
P2860
Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Reduced intensity versus myelo ...... e and acute lymphoid leukemia.
@en
Reduced intensity versus myelo ...... e and acute lymphoid leukemia.
@nl
type
label
Reduced intensity versus myelo ...... e and acute lymphoid leukemia.
@en
Reduced intensity versus myelo ...... e and acute lymphoid leukemia.
@nl
prefLabel
Reduced intensity versus myelo ...... e and acute lymphoid leukemia.
@en
Reduced intensity versus myelo ...... e and acute lymphoid leukemia.
@nl
P1476
Reduced intensity versus myelo ...... e and acute lymphoid leukemia.
@en
P2093
Mitchell E Horwitz
P304
P356
10.1097/CCO.0B013E328342B82A
P577
2011-03-01T00:00:00Z